Ixaka’s cell and gene therapy pipeline utilizes our MCT and TNP technology platforms and is focussed on cardiovascular and cancer indications. We are seeking development and marketing partners to take these products to the market globally.
(1)CELTIC : Chemically Encapsulated Lentiviral vector for Targeted In vivo CAR T-cell therapy